Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for NMRA-898 in Schizophrenia, neuropsychiatric disorders. The expected timing is based on the latest available company guidance and may change.
10/27/25- Initiated Ph1 trial. Update in mid-2026. 11/6/25:- Advancing Ph1 M4 PAM studies; comprehensive franchise update still expected mid-2026. 01/05/26:- Phase 1 M4 PAM trials for NMRA-898/NMRA-861 progressing; comprehensive franchise update planned mid-2026. 03/30/26:- NMRA-898 chosen as lead M4 modulator; ongoing Ph1 schizophrenia study data expected from multiple ascending doses in H2 2026. 05/07/26:- Ongoing Ph1 MAD study in schizophrenia and healthy volunteers; data readout still expected in H2 2026. 08/14/26:- Ph1 MAD study data in stable schizophrenia and healthy volunteers remains expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.